Loading stock data…
VRTX
$445.77+2.81 (+0.63%)
After Hours$445.76-0.01 (-0.00%)· Last close Jun 9
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vertex Pharmaceuticals Incorporated in the Healthcare sector is trading at $445.77. Wall Street consensus targets $548.69 (29 analysts), implying a +23.1% move over the next 12 months. The stock is currently 12% below its 52-week high of $507.92, remaining 1.9% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$445.77
Potential Downside
0%
Whystock Fair Value$445.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus29 analysts
Buy
Mean target$548.69+23.1%
Range$330.00 – $641.00
Fundamentals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.41%
Volume
Today's trading volume
870,795
Recent News
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Mixed Recent Returns And Long Term Shareholder Gains
Stock performance snapshot Vertex Pharmaceuticals (VRTX) is drawing investor attention after recent trading left the stock around US$446.83, with returns mixed across different periods and a longer term track record that stands in contrast to more recent moves. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been choppy, with a 1-day share price return of 1.15% and a 30-day share price return of 4.49%, while the 1-year total shareholder return has slipped 0.81% and the...
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Best Stocks to Invest $500 in Right Now
The market is underestimating these companies' long-term prospects.